TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

Thomas J Louie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.